FY2024 EPS Estimates for Prothena Increased by Analyst

Prothena Co. plc (NASDAQ:PRTA - Free Report) - Equities researchers at Zacks Research raised their FY2024 earnings per share estimates for shares of Prothena in a research report issued on Tuesday, December 3rd. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings of ($2.36) per share for the year, up from their prior estimate of ($2.47). The consensus estimate for Prothena's current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Prothena's Q1 2025 earnings at ($1.33) EPS, Q2 2025 earnings at ($1.38) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at $0.78 EPS, FY2025 earnings at ($3.25) EPS, Q1 2026 earnings at ($1.42) EPS, Q2 2026 earnings at ($1.14) EPS, Q3 2026 earnings at ($0.20) EPS and FY2026 earnings at ($3.11) EPS.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.18) by $0.08. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The business had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.22 million. During the same period in the prior year, the business posted $0.38 earnings per share. The company's revenue was down 98.9% on a year-over-year basis.

Several other brokerages have also issued reports on PRTA. Cantor Fitzgerald reissued an "overweight" rating on shares of Prothena in a report on Monday, September 30th. Oppenheimer cut their price target on Prothena from $66.00 to $62.00 and set an "outperform" rating on the stock in a report on Wednesday, August 14th. Bank of America decreased their price objective on Prothena from $33.00 to $31.00 and set a "neutral" rating for the company in a research note on Tuesday, October 1st. Royal Bank of Canada cut their target price on Prothena from $28.00 to $24.00 and set a "sector perform" rating on the stock in a research note on Friday, August 9th. Finally, StockNews.com downgraded shares of Prothena from a "hold" rating to a "sell" rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.86.

Prothena Trading Up 0.9 %

Prothena stock traded up $0.12 during mid-day trading on Friday, hitting $14.05. The stock had a trading volume of 259,188 shares, compared to its average volume of 450,329. The firm's 50 day moving average is $16.25 and its 200 day moving average is $19.56. Prothena has a one year low of $13.22 and a one year high of $41.54.

Institutional Investors Weigh In On Prothena

Several institutional investors have recently added to or reduced their stakes in PRTA. Wellington Management Group LLP raised its position in shares of Prothena by 14.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,178,788 shares of the biotechnology company's stock valued at $69,911,000 after purchasing an additional 539,359 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Prothena by 42.3% in the second quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company's stock worth $32,198,000 after buying an additional 464,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Prothena by 5.1% in the first quarter. Vanguard Group Inc. now owns 1,125,283 shares of the biotechnology company's stock worth $27,873,000 after buying an additional 54,728 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Prothena by 1,122.9% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company's stock worth $8,812,000 after buying an additional 483,673 shares during the period. Finally, Systematic Financial Management LP grew its holdings in shares of Prothena by 25.8% during the second quarter. Systematic Financial Management LP now owns 193,763 shares of the biotechnology company's stock valued at $3,999,000 after buying an additional 39,771 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company's stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.